<DOC>
	<DOCNO>NCT00857220</DOCNO>
	<brief_summary>A multicenter study evaluate safety eszopiclone child ( 6 11 year age , inclusive ) adolescent ( 12 17 year age , inclusive ) attention deficit/hyperactivity disorder ( ADHD ) associate insomnia .</brief_summary>
	<brief_title>Long Term Safety Study Study Drug ( Eszopiclone ) Children Adolescents With ADHD -Associated Insomnia</brief_title>
	<detailed_description>This multi center , open label , long term safety study pediatric subject 6 17 year age , inclusive , diagnosis ADHD associate insomnia . Subjects complete Study 190 246 ( Rollover subject ) meet study enrollment criterion allow participate long term safety study . Additionally , Treatment naïve subject enrol long term safety study order meet overall subject enrollment objective obtain 100 subject 12 month treatment . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Subject male female 6 17 year age , inclusive , time consent . Subject must diagnosis ADHD define DSMIV criterion • The diagnosis Rollover subject take Screening visit Study 190 246 . Treatment naïve subject assessment perform Screening visit . Subject must document ADHD associate insomnia , define subject subject 's parent/legal guardian report repeat difficulty sleep initiation ( sleep latency &gt; 30 minute ) consolidation ( wake time sleep onset &gt; 45 minute ) , &gt; despite adequate age appropriate time opportunity sleep . Subject either &gt; 30 minute latency persistent sleep ( LPS ) &gt; 45 minute wake time sleep onset ( WASO ) demonstrate PSG . Subject subject 's parent/legal guardian report daytime functional impairment result sleep problem . Subject subject 's parent/legal guardian report attempted fail behavioral intervention sleep problem , include regular bedtime rise time . Subject 's sleep disturbance must attributable either direct physiologic effect drug abuse misuse prescribe medication whether use intend illicit manner . Female subject ≥8 year age must negative serum pregnancy test screening Subject must good general health . Subject must able swallow tablet . If subject currently take medication ADHD , must stable dose regimen least one month , preferably least 3 month prior time consent Subject weight &lt; 10th percentile age gender Subject clinically significant unstable medical abnormality/illness Subject document history Bipolar I II Disorder , major depression , conduct disorder , generalize anxiety disorder ( obsessivecompulsive disorder ) history psychosis , determine medical psychiatric history determine clinical interview use MINIKid Visit 1 . Subject periodic limb movement &gt; 5 time per hour , demonstrate PSG . Subject sleep disorder breathing , demonstrate PSG . Subject another primary sleep disorder ( secondary sleep disorder cause clinical impairment know suspected medical psychiatric condition affect may affect sleep Subject history circadian rhythm disorder travel across ≥3 time zone study . Subject organic brain disease , history febrile seizure . Subject , opinion investigator , suicidal homicidal risk . Female subject pregnant , lactate plan become pregnant . Subject take psychotropic disallow medication , Subject history severe allergies 1 class medication multiple adverse drug reaction . Subject history allergic reaction know suspected sensitivity racemic zopiclone , eszopiclone , substance contain formulation . Subject history alcohol substance abuse within 3 month study participation Subject participate investigational study within 30 day prior study entry currently participate another clinical trial , except Study 190 246 .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hypnotic</keyword>
	<keyword>Eszopiclone</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescent</keyword>
</DOC>